Recent studies have demonstrated that blocking TGF‐β signaling in CD4+T cells remodeled the tumor microenvironment and restrained cancer progression [29] and depletion of transforming growth factor‐β receptor 2 (TGFBR2) in CD4+ T cells promoted cancer progression [30]. The gene discussed is TGFBR2; the disease is neoplasm.